Here’s why stem cell transplants belong in a longevity conversation at all: they are, in large part, a disease of getting older. The patients who need them skew heavily toward late middle age and beyond, and as the global population ages, demand for safer transplants is only going up.
Every improvement in how doctors manage the immune system after a transplant doesn’t just treat one disease; it chips away at one of the harder trade-offs in aging medicine: a treatment that might work, versus one that might seriously hurt the person receiving it. That’s the problem a new grant from DKMS, the international blood stem cell donor organization, wants a new generation of scientists to take on.
DKMS opened applications this month for its John Hansen Research Grant 2027, worth close to $1.08 million (€1 million) total, split among early-career scientists, anyone who’s held a doctorate for ten years or less. The grant has run since 2015 and has quietly funded work on some of the field’s toughest, most persistent problems: transplant complications, donor matching, and diagnostics that catch trouble early [1].
The basic idea behind a stem cell transplant is this: wipe out a patient’s diseased bone marrow, replace it with a donor’s healthy cells, and let those new cells rebuild the immune system from scratch. When it works, the donor’s immune cells go hunting for anything left behind and destroy it, something researchers call graft-versus-leukemia activity. That’s the goal.
But immune cells don’t always know where to stop. Sometimes they can’t tell the difference between a leftover cancer cell and a patient’s own healthy liver, skin, or gut. That’s graft-versus-host disease, and it can be brutal, in some cases more dangerous than the original diagnosis.
Finding ways to keep the beneficial part of that immune response while dialing back the harmful part is one of transplant medicine’s oldest unsolved problems, and it’s exactly what this funding is meant to chip away at. Eligible projects span cell therapy, transplant immunology, donor selection, and new diagnostic tools.
John A Hansen spent his career at Fred Hutchinson Cancer Research Center in Seattle before he died in 2019. His research is a big reason transplant matching works as well as it does today. Hansen helped figure out how to use HLA, essentially a genetic ID tag, to match donors and patients in a way that cuts down on complications. Before that kind of matching got precise, transplants were a lot closer to guesswork.
Professor Johannes Schetelig, who stepped into the role of DKMS Group’s Global Chief Scientific Officer this past July, says the grant isn’t just about writing checks. He wants young researchers connected to each other, since the resources this kind of work needs – patient samples, specialized labs, transplant data – are rarely sitting in one place. A lot of good ideas stall out simply because the right collaborators never find each other. That’s the gap he’s trying to close.
DKMS didn’t stop at one grant. It also opened its Impact Grant 2027, aimed specifically at hospitals and researchers in Central and South America, Africa, and South and Southeast Asia, regions where transplant infrastructure is often thin on the ground. It’ll fund up to three projects at $129,600 (€120,000) each, over two years. The thinking here is straightforward: don’t just export research built for wealthy hospitals; fund the people already working the problem locally.
Blood cancer skews older. As more of the world lives longer, more people will need transplants, and the margin between a transplant that cures someone and one that harms them badly needs to get wider, not stay where it is. That’s not the kind of progress that makes for dramatic headlines. It’s slow, it’s technical and most of the people it eventually helps will never know a grant like this existed.
But that’s usually how it goes with the science that extends healthy years. It’s not one dramatic cure. It’s a hundred small fixes, made by researchers who got funded early enough to keep working on a hard problem instead of giving up on it. $1.08 million isn’t going to solve graft-versus-host disease by itself. It might just keep the right person in the lab a little longer.
[1] https://www.eurekalert.org/news-releases/1140150

Kyle Umipig
Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Advertise

Contact
NEWS
DATA
PODCAST
CLINICS
Longevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643
First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest. First Longevity Limited does not give advice on the risks of investment and is not authorised to carry out investment business under the Financial Services and Markets Act 2000 (“FSMA”).
The content on this website has not been approved by an authorised person within the meaning of FSMA, for the purposes of section 21 of FSMA and reliance on information on this website for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of their property or other assets involved.
Users of this website should not treat its contents as constituting advice relating to legal, taxation or investment matters and are advised to consult their own professional advisers authorised under FSMA who specialize in advising on such matters.
The information included in this website and Longevity.Technology System is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.